Triple

T11290983
Position Surface form Disambiguated ID Type / Status
Subject Stanley N. Cohen E267321 entity
Predicate knownFor P22 FINISHED
Object Cohen–Boyer recombinant DNA patents
The Cohen–Boyer recombinant DNA patents were foundational biotechnology patents that covered key methods for creating recombinant DNA, enabling modern genetic engineering and the biotechnology industry.
E915626 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Cohen–Boyer recombinant DNA patents | Statement: [Stanley N. Cohen, knownFor, Cohen–Boyer recombinant DNA patents]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Cohen–Boyer recombinant DNA patents
Context triple: [Stanley N. Cohen, knownFor, Cohen–Boyer recombinant DNA patents]
  • A. Bayh–Dole Act
    The Bayh–Dole Act is a landmark 1980 U.S. law that allows universities, small businesses, and other institutions to retain ownership of inventions developed with federal funding, spurring technology transfer and commercialization.
  • B. Technical Corrections to the Bayh–Dole Act
    Technical Corrections to the Bayh–Dole Act is a legislative measure that refined and clarified the original Bayh–Dole Act’s provisions governing the ownership and commercialization of inventions arising from federally funded research.
  • C. CRISPR-Cas9 gene-editing technology
    CRISPR-Cas9 gene-editing technology is a revolutionary molecular tool that allows scientists to precisely modify DNA within living organisms, transforming research, medicine, and biotechnology.
  • D. Association for Molecular Pathology v. Myriad Genetics, Inc.
    Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.
  • E. Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure
    The Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure is an international agreement that standardizes how deposits of microorganisms are recognized for patent applications, allowing a single deposit at an approved authority to be accepted by all member states.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Cohen–Boyer recombinant DNA patents
Triple: [Stanley N. Cohen, knownFor, Cohen–Boyer recombinant DNA patents]
Generated description
The Cohen–Boyer recombinant DNA patents were foundational biotechnology patents that covered key methods for creating recombinant DNA, enabling modern genetic engineering and the biotechnology industry.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Cohen–Boyer recombinant DNA patents
Target entity description: The Cohen–Boyer recombinant DNA patents were foundational biotechnology patents that covered key methods for creating recombinant DNA, enabling modern genetic engineering and the biotechnology industry.
  • A. Bayh–Dole Act
    The Bayh–Dole Act is a landmark 1980 U.S. law that allows universities, small businesses, and other institutions to retain ownership of inventions developed with federal funding, spurring technology transfer and commercialization.
  • B. Technical Corrections to the Bayh–Dole Act
    Technical Corrections to the Bayh–Dole Act is a legislative measure that refined and clarified the original Bayh–Dole Act’s provisions governing the ownership and commercialization of inventions arising from federally funded research.
  • C. CRISPR-Cas9 gene-editing technology
    CRISPR-Cas9 gene-editing technology is a revolutionary molecular tool that allows scientists to precisely modify DNA within living organisms, transforming research, medicine, and biotechnology.
  • D. Association for Molecular Pathology v. Myriad Genetics, Inc.
    Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.
  • E. Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure
    The Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure is an international agreement that standardizes how deposits of microorganisms are recognized for patent applications, allowing a single deposit at an approved authority to be accepted by all member states.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d6aac993a08190a6f36445ebaf9a43 completed April 8, 2026, 7:21 p.m.
NER Named-entity recognition batch_69d7e989fdac81909a4a75f1f68b55c6 completed April 9, 2026, 6:01 p.m.
NED1 Entity disambiguation (via context triple) batch_69e4f49badc88190a3195e919900f0c3 completed April 19, 2026, 3:28 p.m.
NEDg Description generation batch_69e4f95cbc7c819082e3d7c3c3266708 completed April 19, 2026, 3:48 p.m.
NED2 Entity disambiguation (via description) batch_69e4ff73f3348190abfd28f716c61105 completed April 19, 2026, 4:14 p.m.
Created at: April 8, 2026, 9:32 p.m.